A 15-year-old boy with severe combined immunodeficiency, fungal infection, and weight gain

Mehtap Haktanir Abul1, Karen Tuano, C Mary Healy

  • 1Section of Immunology, Allergy and Rheumatology, Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.

Insights

Hematopoietic stem cell transplantation (HSCT) is most effective for X-linked severe combined immune deficiency in infants under 3 months without other health issues. Suboptimal outcomes can still occur, leading to infections and complications from antifungal treatments.

Area of Science:

  • Immunology
  • Hematology
  • Pediatric Medicine

Background:

  • X-linked severe combined immune deficiency (X-linked SCID) requires timely intervention for optimal outcomes.
  • Hematopoietic stem cell transplantation (HSCT) is a primary treatment for X-linked SCID.
  • Early diagnosis and treatment are critical for improving patient survival and quality of life.

Observation:

  • HSCT outcomes in X-linked SCID are best in patients under 3 months old, without comorbidities, and with matched sibling donors.
  • Incomplete cellular engraftment can lead to persistent immune dysfunction, affecting B and natural killer cell function.
  • Protein-losing enteropathies and low immunoglobulin levels (IgA, IgG, IgM) can occur with immune deficiencies.

Findings:

  • Even with optimal conditions, HSCT may not achieve full engraftment, resulting in suboptimal immune reconstitution.
  • Patients with immune deficiencies are susceptible to specific infections predicted by their immune dysfunction.
  • Fungal infections, though rare in immunocompromised hosts, require careful evaluation and management due to potential drug-drug interactions with antifungals.

Implications:

  • Early HSCT in X-linked SCID is crucial, but strategies are needed to address suboptimal engraftment and immune function.
  • Understanding infection risks associated with specific immune deficiencies can guide proactive monitoring and treatment.
  • Managing coexisting fungal infections in immunocompromised patients necessitates careful consideration of antifungal therapy and potential drug interactions.

Related Concept Videos

Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
3.1K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.4K
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
30
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
727
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
622
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
685